INTUITIVE SURGICAL INC Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Business Highlights: Q3 was strong with worldwide procedure growth, capital placements, and increased utilization. Da Vinci V saw global adoption, with first systems placed in Japan and Europe. Procedures for 19% and ION were up, system utilization improved.
• Clinical and Product Updates: Hosted Intuitive 360 user conference. Da Vinci V utilization validated design intent. ION procedures grew 52%, received FDA clearance for software release. SP procedures increased 91%. Recent 510(k) clearances supported SP stapler usability.
• Priorities: Focus on full launch of da Vinci V, increased adoption of focused procedures, building industrial scale and manufacturing optimization, and excellence of digital tools.

Segment Performance

• Procedures: Total worldwide procedure growth was 20%. Da Vinci procedures grew 19%, ION procedures were up 52%. System utilization: da Vinci SP grew 4%, ION grew 14%. Da Vinci V utilization outpaced Xi in the first 18 months since launch.
• Capital: Placed 427 da Vinci systems (including 240 da Vinci V, 30 SP, 50 ION). Da Vinci V upgrades drove strong domestic placements. Internationally, placed first systems in Japan and Europe.
• Revenue: Q3 revenue grew 23% to $2.5 billion. Recurring revenue grew 21%, accounting for 85% of total revenue. Pro forma gross margin was 68% in Q3, down from 69.1% in Q3 last year.

Guidance

• Da Vinci Procedure Growth: Updated 2025 da Vinci procedure growth guidance to 17-17.5% (previously 15.5-17%).
• Gross Profit: Pro forma gross margin guidance updated to 67-67.5% of revenue (previously 66-67%). Tariff impact expected to be 70 basis points plus or minus 10 basis points.
• Operating Expenses: Pro forma operating expense growth expected to be between 11-13%.
• Other Income: Forecast other income to total between $350 million and $360 million.
• Capital Expenditures: Expected to range between $625 million and $675 million.
• Tax Rate: Estimated 2025 pro forma income tax rate to be between 21-22%.

Risks

• Tariffs: Year-over-year decline in gross margin reflects 90 basis point impact from tariffs, partially offset by cost reductions.
• Government Budgets: Challenges in Japan and the UK due to government budget constraints.
• Market Competition: Constrained and competitive marketplace in China, with price pressure on capital and INA sides.

Q: Robert Marcus asked about procedures trends, sustainability, and refurbished XIs.

A: David J. Rosa discussed US and OUS procedure growth drivers, da Vinci V's role, and refurbished XI as part of the portfolio.

Q: Travis Steed asked about US utilization and refurbished XIs.

A: Jamie E. Samath and David J. Rosa talked about US utilization focus on customer segments and refurbished XI as part of portfolio flexibility.

Q: Larry Biegelsen asked about US utilization and margins.

A: Jamie E. Samath discussed US utilization focus on customer segments and margin outlook, and David J. Rosa spoke about da Vinci V's role.

Q: Rick Wise asked about bariatrics and China.

A: Dan Connolly and Jamie E. Samath discussed bariatrics decline and China's constrained competitive environment.

Q: Patrick Wood asked about haptics, force feedback, and IonSP.

A: David J. Rosa talked about force feedback's impact on outcomes and IonSP's performance.

Q: Adam Maeder asked about da Vinci V OUS launch.

A: Jamie E. Samath and David J. Rosa discussed early feedback and rollout strategy in Europe and Japan